A : Telescopic vielV (0°, 4 nun) of the right nasal cavity shows the concha bullosa of the right middle turbinate. B: Coronal CT of the sinuses shows the concha bullosa and reveals that the right middle turbinate is partially filled with secretions. C: Af ter the concha bullosa has been opened with a microdebrider; telescopic vieIV (0°, 4 nun) shows that it contains thick inspissated material. D: Further resection reveals that the inspissated material had filled the inf erior two-thirds of the right concha bullosa. epididymis, spermduct, prostate, seminal vessicle,Cowper' s gland and accessory glands. The relevance ofthisstudyfor shorttermtopica l oti c useis unknown.
A 38-yea r-old woman presented with a 2-ye ar history of recurring pain medial to the right eye and associated nasal congestion. Her family physician had treated her repeatedly with antibiotics, but the resoluti on ofsymptoms was only temporary.
Clinical examin ation revealed the presence of a concha bullosa of the right middl e turbinate (figure, A). Comp uted tomography (CT) showed that the sinuses were clear, but the right middle turbinate was partially filled with secretions (figure, B). In view of the recurri ng natur e of her symptoms, the patient elected to undergo a partia l resection of the infected right midd le turbin ate; this was accomplished with a microdebrid er (figure, C). Intraoperative findings includ ed the presence of thick inspissated material that had filled the infer ior two-thi rds of the right midd le turbi nate (figure, D) . At the termination of the procedure, the lateral 
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Thefollowing treatment-rel atedadverseeventswereeach reporte d10 a smgle patienttympanostomy tube blockage; ear pruritus; tinnitus; oral moniliasis; crying; dizziness; and erythe ma. Acute Otitis Extema: The followingtreatment-relatedadve rseeventsoccurred in 0.4% or more ofthe patients with intact tympanic membranes.
Pregnancy
Teratogenic Effects. Pregnancy CategoryC: Reproduction studieshave been performed in rats and mice usingoral doses of up to 100 mg/kg and IV doses up to 30 mg/kgand have revealed no evidence of harm to the fetus as a result of ciprofloxacin. In rabbits, ciprofloxacin (30 and 100 mg/kg orally) produced gastrointestinal disturb ances resulting in maternal weight loss and an increase d incidence of abortion, but noteratogenicity wasobserved at either dose. Afte r intravenous administrationofdoses up to 20mg /kg, no maternal toxic itywas prod uced in the rabbit, and no emb ryotoxicity or teratoge nicitywasobserved.
Co rticosteroids are generally teratogenic in laboratory anima lswhen administered systemically at relatively lowdosage levels. The more potent cort icosteroids have been shown to beteratogenic afte r dermal application in laboratory animals. Anima l reproduction studieshave notbeen conducted withC HOW SUPPLIED CI PRODEX' (ciprofloxacin 0.3% and dexamethasone 0.1%)Sterile Otic Suspension is supplied as foll ows: 5 mL fill and 7.5 mL fill in a ORO P-TAI NER" system. The DROP-TAINE R" system consists of a natural polyethylene bottle and natural plug,with a white polypropylene closure. Tamper evidence is provided with a shrink band around the closure and neck area of the package. NDC 0065-8533-01. and 89%, respectively, for otic suspension containing neomycin 0.35%, polymyxin B 10,000 IU/mL, and hydrocortisone 1. 0% (neo/poly /HC). Amon g culture positive patientsclinical cures were 86%and 92%for CIPRODEX' Ot ic compared to 84% and 89%, respectively, for neo/poly/HC. Microbiological eradication rates for these patients inthe same clinicaltrials were 86% and92% for CIPRODEX' Otic compared to 85% and 85%, respectively, for neo/poly/HC.
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STERILE OTIC SUSPENSION
DESCRIPTIO N CI PRD DEX'lciprofloxacin 0.3% and dexamethasone 0.1%) Sterile Ot ic Suspension contains the synthetic broad-spectrum antibacterial agent. ciprofloxacin hydrochloride, combined with the a nt i . inflammatoc orticosteroid, dexamethasone, in a sterile, preserved suspension for otic use. Each mL of CIPR ODEX Otic containsciprofloxacin hydrochloride (equival ent to 3 mg ciprofloxacin base), 1 mg dexamethasone, and 0.1mg benzalkoni umchloride asa preservative . The inactive ingredientsare boric acid. sodium chloride, hydroxyethylcellulose, tvloxapc', acetic acid, sodium acetate, edetate disodium, and purifiedwater. Sodiumhydroxide or hydrochloric acid may be added for adjustment ofpH. Ciprofloxacin, a tluoroquinolone is available as the monohydro chloride monohydrate salt of t-cvclopropyl-6-fluoro-l,4-dihydro-4-oxo-7-(1-piperazinyl)-3-quinoli necarboxyl ic acid. The empi rical form ula is C17H 18FN3D3·HCI·H2D. Dexamethasone, 9-tluoro-ll (beta).17,21-trihydroxy-16{alpha)-methylpregna-l, 4-diene-3,20-dione, is an anti-i nfla mmatorycorticosteroid. The empiricalformu la is Cn H29F05. CLINICAL PHARMACOLOGY Pharmacokinetics: Following a single bilateral4-drop(total dose = 0.28 mL, 0.84 mg ciprofloxacin, 0.28mg dexamethasone) topical otic dose of CIPRODEX' Ot ic to pediatric patients after tympanostomy tube insertion, measurable plasma concentrationsof ciprofloxa cin and dexamethasone were observe d at 6 hours following administrationin 2 of 9 patients and5 of9 patients, respectively.
Mean ± SO peak plasma concentrations of ciprotl oxacin were 1. 39 ± 0.880 ng/mL (n=9). Peak plasma concentrations ranged from 0.543 ng/mL to 3.45 ng/mL and were on average approximate ly 0.1% of of quinolones, including ciprofloxacin at doses much higher than given or absorbed by the otic route, has led to lesions or erosions of the cartilage in weight-bearing joints and other signs of arthropathy in immature ani mals of variousspecies. Gui nea pigs dosed in the middle ear with CIPRODEX'!lOtic for one mont h exhibitednodrug-relatedstructural or functionalchanges ofthecochlea r hair cells and nolesions in the ossicles. CIPROD EX' Otic was also shown to lack dermal sensiti zing potential in the guinea p iw hen tested accordingto the method of Buehler. No signsof local irri tationwere found when CIPROD EX Otic was applied topically in the rabbiteye. Information for Patients: For otic use only .IThisproduct is not app roved foruse inthe eye.) Warmthe bottlein you r hand foronetotwominutes priorto useandshake well imm ediately before usi ng. Avoid contaminati ngthe tip with material from the ear,fingers, or other sources. Protectfrom light. If rash or allergic reaction occurs, discontinue use immediately andcontact your physician. It is very important to use the ear drops for as long asthe doctor hasinstructed, even if the sympt omsimprove.Di scardunused portio n aftertherapyis comp leted.Acute OtitisMedia inpedi atric patients with tympanostomvtubes: Prior to administrationof CIPRO DEX' Otic in patients 16 months and older) with acute otitis media through tympanostomytubes, the solution should be warmed by holding 
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and inferior portions of the right concha bullo sa had been resected, pro viding adeq uate drainage and ventilat ion.
A concha bullosa of the middle turbinate is a common finding in the nose. By narrowing the midd le meat us, such a lesion can predispose a patient to sin usitis .1When a concha bullosa is suspected of causing recurrent middle meatal and sinus obstruction, the middle meatu s can be widened with a partial resection. We have previously described an effective techniq ue for partial resection of the latera l port ion of a concha bullosa using powered instrumentation . ' It is believed that a concha bullosa of the midd le turbinate usually drains direct ly into the ethmoid sinu s.' Variations of this drainage pattern have been described.v' When drainage and vent ilatio n of a conc ha bullosa are disturbed, the conc ha bullosa might become infected and cause recurrent sinu s headache.
The case described here involved an unus ual isolated recurrent infection of a concha bullosa without involvement of the paranasal sinuse s.
